{"id":55088,"date":"2012-04-26T11:12:41","date_gmt":"2012-04-26T11:12:41","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=55088"},"modified":"2026-04-03T07:42:25","modified_gmt":"2026-04-03T07:42:25","slug":"tranzactie-la-varful-pietei-de-medicamente-americanii-de-la-watson-cumpara-actavis-pentru-4-mld-euro","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=55088","title":{"rendered":"Tranzac\u0163ie la v\u00e2rful pie\u0163ei de medicamente: americanii de la Watson cump\u0103r\u0103 Actavis, pentru 4 mld. euro"},"content":{"rendered":"<p>Achizi\u0163ia va fi un avantaj pentru Watson \u00een competi\u0163ia cu rivali precum Teva Pharmaceuticals \u015fi Sandoz, divizie a Novartis. Sectorul medicamentelor generice a consemnat \u00een ultimii ani un val de fuziuni \u015fi achizi\u0163ii \u00eentre companii, odat\u0103 cu presiunile exercitate de guverne asupra industriei, constr\u00e2ns\u0103 s\u0103 comercializeze produse la pre\u0163uri c\u00e2t mai mici. Astfel, condi\u0163iile actuale din sectorul genericelor favorizeaz\u0103 companiile mari, care pot produce la cele mai mici costuri. Watson va pl\u0103ti 4,25 miliarde euro \u00een cash pentru Actavis, iar ac\u0163ionarii companiei elve\u0163iene ar putea \u00eencasa pl\u0103\u0163i estimate la 250 milioane euro dac\u0103 vor fi atinse anumite \u0163inte de performan\u0163\u0103 pentru acest an.<\/p>\n<p><a href=\"http:\/\/www.zf.ro\/business-international\/tranzactie-la-varful-pietei-de-medicamente-americanii-de-la-watson-cumpara-actavis-pentru-4-mld-euro-9573644\" target=\"_blank\">Mai multe pe mediafax.ro<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Grupul american Watson Pharmaceuticals va prelua compania elve\u0163ian\u0103 Actavis Group pentru cel pu\u0163in 4,25 miliarde euro, pentru a-\u015fi consolida pozi\u0163ia pe pia\u0163a medicamentelor generice \u015fi a-\u015fi extinde prezen\u0163a interna\u0163ional\u0103, transmite Reuters.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[511],"tags":[8450,8088,11060,400,21167],"class_list":["post-55088","post","type-post","status-publish","format-standard","hentry","category-afaceri","tag-actavis","tag-farma","tag-generice","tag-tranzactie","tag-watson"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/55088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55088"}],"version-history":[{"count":1,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/55088\/revisions"}],"predecessor-version":[{"id":71572,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/55088\/revisions\/71572"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}